DeepMed Research

Iloperidone

Generic Name: Iloperidone

Brand Names: Fanapt

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₇FN_₂O_₄

CAS Number: 133454-47-4

Unique Ingredient Identifier: VPO7KJ050N

Background: Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009.

Indication: Treatment of acute schizophrenia.

Associated Conditions: Schizophrenia

Clinical Trials

Open-Label Evaluation of Relapse Prevention in Patients With Schizophrenia

Phase 3

Not yet recruiting

Conditions: Schizophrenia

Interventions: Drug: iloperidone

First Posted Date: 2025-05-08

Last Posted Date: 2025-05-08

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT06961968

Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions

Phase 1

Not yet recruiting

Conditions: Schizophrenia
Bipolar I Disorder

Interventions: Drug: VHX-896 and iloperidone
Drug: Iloperidone and VHX-896

First Posted Date: 2024-07-10

Last Posted Date: 2024-07-10

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT06494397

Locations: 🇺🇸
Vanda Investigational Site, Marlton, New Jersey, United States

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

Phase 4

Recruiting

Conditions: Schizophrenia
Bipolar I Disorder

Interventions: Drug: Iloperidone

First Posted Date: 2022-12-13

Last Posted Date: 2025-03-04

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT05648591

Locations: 🇺🇸
Vanda Investigational Site, Everett, Washington, United States

A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

Phase 2

Withdrawn

Conditions: Parkinson Disease Psychosis

Interventions: Drug: Iloperidone

First Posted Date: 2022-04-25

Last Posted Date: 2024-03-21

Lead Sponsor: Vanda Pharmaceuticals

Registration Number: NCT05344365

Locations: 🇺🇸
Vanda Investigational Site, Saint Petersburg, Florida, United States

Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: VHX-896 and iloperidone
Drug: Iloperidone and VHX-896

First Posted Date: 2021-07-20

Last Posted Date: 2022-07-11

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT04969211

Locations: 🇺🇸
Vanda Investigational Site, Springfield, Missouri, United States

Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

Phase 3

Completed

Conditions: Bipolar I Disorder

Interventions: Drug: Iloperidone Placebo
Drug: Iloperidone

First Posted Date: 2021-03-29

Last Posted Date: 2024-04-18

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 417

Registration Number: NCT04819776

Locations: 🇵🇱
Vanda Investigational Site, Tuszyn, Poland

A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Iloperidone

First Posted Date: 2021-01-15

Last Posted Date: 2023-06-29

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT04712734

Locations: 🇺🇸
Vanda Investigational Site, Marlton, New Jersey, United States

Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

Phase 1

Completed

Conditions: Bipolar I Disorder
Schizophrenia

Interventions: Drug: Iloperidone

First Posted Date: 2019-10-15

Last Posted Date: 2020-04-13

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT04127058

Locations: 🇺🇸
Vanda Investigational Site, Marlton, New Jersey, United States

Human Bioequivalence Test (Fasting & Postprandial) of Iloperidone Tablets

Phase 1

Conditions: Bioequivalence

Interventions: Drug: Iloperidone 1 MG
Drug: Placebo
Dietary Supplement: postprandial
Dietary Supplement: fasting

First Posted Date: 2018-02-05

Last Posted Date: 2018-02-05

Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT03420534

Locations: 🇨🇳
The first affiliated hospital of zhengzhou university., Zhengzhou, Henan, China

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed

Conditions: Schizophrenia

Interventions: Other: Caregiver psycho-education and skills training
Other: Caregiver support available at the study site
Drug: Paliperidone palmitate
Drug: Chlorpromazine
Drug: Droperidol
Drug: Fluphenazine
Drug: Haloperidol
Drug: Loxapine
Drug: Perphenazine
Drug: Pimozide
Drug: Prochlorperazine
Drug: Thiothixene
Drug: Thioridazine
Drug: Trifluoperazine
Drug: Aripiprazole
Drug: Asenapine
Drug: Clozapine
Drug: Iloperidone
Drug: Olanzapine
Drug: Paliperidone
Drug: Quetiapine
Drug: Risperidone
Drug: Ziprasidone

First Posted Date: 2015-11-09

Last Posted Date: 2019-01-23

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 296

Registration Number: NCT02600741

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy